Tildipirosin (Zuprevo)

Tildipirosin, marketed under the brand name Zuprevo, represents a newer generation macrolide antibiotic developed specifically for the treatment and control of respiratory disease in cattle and swine. This 16-membered ring macrolide was designed to address the unique pharmacokinetic requirements of food animal medicine, offering prolonged tissue concentrations that support single-dose treatment protocols. The drug's molecular structure provides excellent penetration into respiratory tissues where bacterial pathogens reside, making it particularly effective against the complex of organisms responsible for bovine and swine respiratory disease.

The mechanism of action of tildipirosin, like other macrolide antibiotics, involves inhibition of bacterial protein synthesis through binding to the 50S ribosomal subunit. This binding prevents the translocation of peptidyl-tRNA during protein synthesis, resulting in bacteriostatic activity against susceptible organisms. Tildipirosin demonstrates concentration-dependent accumulation in lung tissue and pulmonary alveolar macrophages, achieving and maintaining concentrations far exceeding those in plasma. This tissue-targeting property is fundamental to the drug's efficacy against respiratory pathogens and supports its use in both treatment and metaphylactic control programs.

The commercial formulation of tildipirosin is presented as a sterile injectable solution at a concentration of 180 mg/mL, designed for subcutaneous administration. This relatively high concentration allows for reasonable injection volumes even in larger animals, minimizing tissue trauma and injection site reactions. The formulation has been optimized for stability and bioavailability, with excipients selected to provide rapid absorption while maintaining product integrity throughout its shelf life. The solution appears as a clear to slightly yellow liquid and should be examined before use to ensure no visible particles or discoloration are present.

Regulatory approval for tildipirosin includes indications in both cattle and swine, making it one of the more versatile macrolide antibiotics in food animal medicine. The FDA has approved its use for treatment of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in cattle, as well as swine respiratory disease caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Bordetella bronchiseptica. The drug requires a veterinary prescription and must be used within the context of a valid veterinarian-client-patient relationship. Specific restrictions apply to its use in dairy cattle of breeding age and other categories as detailed on the product label.

The primary indication for tildipirosin in cattle is the treatment of bovine respiratory disease (BRD), the most economically important disease affecting the cattle industry worldwide. BRD is a multifactorial disease complex involving viral agents, bacterial pathogens, environmental stressors, and host immune factors. Tildipirosin has demonstrated efficacy against the major bacterial components of this complex, including Mannheimia haemolytica, the primary bacterial pathogen causing fibrinous bronchopneumonia, Pasteurella multocida, a common secondary invader, and Histophilus somni, which causes both respiratory and systemic disease. These organisms are susceptible to macrolide antibiotics and represent appropriate targets for tildipirosin therapy.

Beyond treatment of established disease, tildipirosin carries an important indication for the control of respiratory disease in cattle at high risk of developing BRD. This metaphylactic application is particularly valuable in feedlot operations where newly arrived cattle face significant disease pressure from the combined effects of transportation stress, commingling with cattle from diverse sources, dietary transitions, and exposure to novel pathogens. By administering tildipirosin to at-risk populations upon arrival processing, veterinarians can significantly reduce the incidence and severity of respiratory disease outbreaks. The single-dose administration is particularly suited to the logistics of feedlot arrival processing where cattle are already being handled for other procedures.

In swine production, tildipirosin is approved for the treatment and control of swine respiratory disease (SRD), a similarly complex condition affecting pig health and productivity. The approved bacterial pathogens in swine include Actinobacillus pleuropneumoniae, the causative agent of porcine pleuropneumonia, Pasteurella multocida, Haemophilus parasuis which causes Glässer's disease, and Bordetella bronchiseptica, a component of atrophic rhinitis complex. These organisms represent the major bacterial contributors to respiratory disease losses in swine production, and tildipirosin's spectrum of activity provides coverage against this important pathogen panel.

The application of tildipirosin in swine respiratory disease includes both treatment of clinical disease and metaphylactic control in groups at elevated risk. Weaning, movement to grow-finish facilities, and mixing of pigs from different sources all create conditions conducive to respiratory disease outbreaks. The ability to provide extended antimicrobial coverage with a single injection makes tildipirosin an attractive option for swine production systems where repeated handling and injection add labor costs and animal stress. The drug's pharmacokinetic profile supports therapeutic tissue concentrations throughout the critical period following weaning or movement when disease risk is highest.

Extra-label use of tildipirosin may be considered by veterinarians in situations where the approved indications do not precisely fit the clinical scenario. Any extra-label use must comply with AMDUCA requirements, including the existence of a valid VCPR, documentation that no approved drug is available for the condition being treated, appropriate record-keeping, and assignment of an extended withdrawal period to ensure food safety. Extra-label use requires careful professional judgment regarding the appropriateness of the drug for the specific situation and species involved.

The approved dosage of tildipirosin for cattle is 4 mg per kilogram of body weight (4 mg/kg), administered as a single subcutaneous injection. Using the commercial 180 mg/mL formulation, this equates to 1 mL per 45 kilograms (99 pounds) of body weight. Accurate weight determination is essential for proper dosing to ensure therapeutic efficacy while avoiding unnecessary overdosing. In feedlot and ranch settings where individual weighing may not be practical for every animal, cattle should be grouped by weight class using visual assessment or scale weights to enable appropriate dosing for each group.

For swine, the approved dosage is also 4 mg per kilogram of body weight (4 mg/kg), administered as a single subcutaneous injection in the post-auricular region (behind the ear). This translates to 1 mL per 45 kilograms of body weight with the 180 mg/mL formulation. In commercial swine operations, pigs may be sorted by weight group to facilitate accurate dosing across a population. The subcutaneous route in the neck area in cattle and behind the ear in swine is selected to minimize potential carcass trim losses at slaughter and to facilitate monitoring of injection site reactions.

The single-dose treatment protocol represents one of tildipirosin's primary advantages in food animal medicine. Following subcutaneous injection, tildipirosin is rapidly absorbed and distributes extensively to respiratory tissues, where it achieves concentrations many times higher than concurrent plasma levels. The drug's extended half-life and tissue persistence support prolonged antimicrobial activity from a single administration, eliminating the need for repeated injections over multiple days. This single-dose approach reduces animal handling, labor requirements, and the cumulative stress of repeated treatments, all of which are significant considerations in commercial livestock operations.

Proper injection technique is critical for achieving optimal therapeutic outcomes and minimizing adverse effects. The injection site should be clean and dry, and aseptic technique should be employed throughout the administration process. Needles of appropriate gauge and length should be selected based on animal size and body condition. For cattle, 16-gauge needles are commonly used, while smaller gauge needles may be appropriate for swine. Multi-dose syringes should be properly calibrated and maintained. A maximum injection volume at any single site is typically 10 mL for cattle, with larger doses divided between two or more injection sites. For swine, lower maximum volumes per site are appropriate given their smaller size.

Metaphylactic use for disease control follows the same dosing regimen as therapeutic treatment. In cattle, administration at arrival processing to feedlots or during other high-risk periods provides protection during the critical window when disease incidence is highest. In swine, metaphylactic treatment may be timed with weaning, movement between facilities, or other recognized risk periods. The goal is to establish therapeutic tissue concentrations before or very early in the disease process, maximizing the opportunity for successful intervention.

Withdrawal time considerations are mandatory for all treated animals destined for human food production. For cattle, the meat withdrawal period is 21 days. For swine, the meat withdrawal period is 7 days. No cattle or swine should be slaughtered for human consumption before the expiration of the appropriate withdrawal period. Tildipirosin is not approved for use in female dairy cattle 20 months of age or older due to milk residue concerns, as no milk withdrawal time has been established. Accurate record-keeping documenting animal identification, treatment date, dosage, and projected withdrawal date is essential for regulatory compliance and food safety assurance.

Tildipirosin is generally well-tolerated in both cattle and swine when administered according to label directions, with a safety profile consistent with other macrolide antibiotics used in food animal medicine. The most commonly reported side effects involve injection site reactions, which are an expected consequence of subcutaneous drug administration in livestock. These local tissue responses are typically mild to moderate in severity and transient in duration, resolving without specific treatment within days to weeks following administration. The incidence and severity of injection site reactions can be influenced by injection technique, needle selection, injection volume, and individual animal factors.

Injection site reactions in cattle may present as transient swelling, firmness, or slight discoloration at the site of administration. Clinical studies documented injection site reactions in a proportion of treated animals, though the majority were classified as mild and resolved spontaneously. The swelling typically reaches its maximum within the first few days after injection and progressively diminishes over the following week or two. Proper injection technique, including appropriate needle selection, site preparation, and limiting injection volume per site, helps minimize local tissue reactions. Administration in the neck region is required to avoid trim losses in valuable carcass cuts should any injection site lesions persist to slaughter.

In swine, injection site reactions following tildipirosin administration are similarly characterized by local swelling and tissue response at the injection site behind the ear. The post-auricular location is selected specifically to minimize carcass impact, as any persistent lesions at this site can be easily trimmed without affecting valuable meat cuts. Studies in swine have demonstrated good local tolerability, though individual variation in tissue response does occur. As with cattle, proper injection technique and equipment selection help reduce the incidence and severity of local reactions.

Systemic side effects following tildipirosin administration are uncommon in both species. Transient reductions in feed intake or mild lethargy have been occasionally reported in the period immediately following treatment, though these effects are typically mild and resolve within 24 to 48 hours. It can be difficult to distinguish drug-related effects from the underlying disease process, particularly since animals receiving treatment are already clinically affected. Gastrointestinal effects such as loose stool or minor digestive upset are possible with any antimicrobial that affects gut flora, though these are not commonly attributed to tildipirosin.

Serious adverse effects are rare when tildipirosin is used appropriately according to label directions. Hypersensitivity reactions can occur with any drug but have not been a prominent feature of tildipirosin's safety profile. Signs of hypersensitivity might include acute swelling, respiratory difficulty, or anaphylactic responses and would require immediate veterinary intervention. The cardiovascular effects that have been associated with some macrolide antibiotics in certain species have not been a significant concern with tildipirosin in approved species at approved doses. However, the product should only be used in approved species, as safety in other species has not been established and could differ significantly.

Tildipirosin is contraindicated in animals with known hypersensitivity to the drug or to other macrolide antibiotics. While true hypersensitivity reactions to macrolides are uncommon, any animal that has previously experienced an allergic or adverse response to tildipirosin or related compounds should not receive the drug. Cross-reactivity between macrolide antibiotics is possible due to structural similarities within the drug class. Animals with documented serious adverse reactions to other macrolides such as tulathromycin, tilmicosin, tylosin, or gamithromycin should be considered for alternative antimicrobial therapy rather than tildipirosin.

The product is specifically contraindicated for use in female dairy cattle 20 months of age or older. This restriction effectively prevents use in lactating dairy cows and reflects the lack of an established milk withdrawal time for tildipirosin. Drug residues in milk represent both a public health concern and a regulatory violation that can have serious consequences for dairy operations. Dairy farms must have robust systems for identifying and segregating animals to ensure that tildipirosin is never administered to cattle that will enter the milking herd before an appropriate withdrawal period could be observed. The 20-month age threshold is designed to capture essentially all cattle entering dairy production.

While tildipirosin is approved for use in swine, it should not be used in pigs destined for breeding without careful consideration of the implications. The drug's effects on reproductive function have not been extensively characterized, and prudent use would avoid treatment of valuable breeding stock unless the benefits clearly outweigh potential risks. For swine destined for slaughter, the approved indications for respiratory disease treatment provide a clear framework for appropriate use within the constraints of withdrawal time requirements.

Use in species other than cattle and swine is not approved and should be approached with extreme caution. Some macrolide antibiotics have demonstrated severe, even fatal, toxicity in certain species. Tilmicosin, for example, causes rapid fatal cardiovascular collapse in horses and swine, though notably tildipirosin is approved for swine where tilmicosin is contraindicated. Nevertheless, the safety of tildipirosin in horses, sheep, goats, and other species has not been established, and use in these species would constitute extra-label use requiring careful risk assessment by a veterinarian. Fatal reactions cannot be ruled out until species-specific safety data are available.

Drug interactions involving tildipirosin in food animal medicine are relatively limited but include several important considerations for practitioners managing cattle and swine health programs. Concurrent administration of multiple macrolide antibiotics should be avoided, as this provides no therapeutic advantage while potentially increasing the risk of adverse effects. Animals receiving tildipirosin should not simultaneously be treated with tilmicosin, tulathromycin, tylosin, gamithromycin, or other macrolide antibiotics. Sequential use of different macrolides within a short timeframe should also be carefully considered, particularly given the extended tissue persistence of some of these drugs.

The interaction between macrolide antibiotics and ionophore feed additives represents a critical consideration in cattle feeding operations. Ionophores including monensin, lasalocid, and laidlomycin are commonly incorporated into cattle rations as growth promotants and coccidiostats. Certain macrolide-ionophore combinations have been associated with toxic reactions, potentially fatal in some cases. While specific interaction data for tildipirosin with ionophores are limited, the general recommendation is to exercise caution when treating cattle consuming ionophore-containing feeds. Consultation with the prescribing veterinarian and nutritionist regarding ionophore feeding programs during tildipirosin treatment is advisable to minimize any potential interaction risk.

Theoretical considerations regarding bacteriostatic versus bactericidal antimicrobial combinations apply to tildipirosin. As a macrolide antibiotic, tildipirosin is generally considered bacteriostatic, inhibiting bacterial growth and replication rather than directly killing organisms. Combination with bactericidal antibiotics such as beta-lactams could theoretically result in antagonistic interactions, as bactericidal drugs typically require actively dividing bacteria for maximum effect. However, the clinical significance of this potential interaction in food animal respiratory disease has not been definitively established, and veterinary judgment guides decisions about combination therapy when indicated by disease severity or suspected resistance patterns.

Metabolic drug interactions involving cytochrome P450 enzyme systems are less well characterized in cattle and swine than in humans or companion animals. Macrolide antibiotics as a class can inhibit certain CYP450 isoforms, potentially affecting the metabolism of other drugs. The practical implications for tildipirosin in food animal medicine are limited, as cattle and swine rarely receive multiple drugs that would be subject to such interactions simultaneously. However, awareness of this potential interaction mechanism is appropriate when animals are receiving multiple medications for any reason.

Human safety precautions are essential when handling and administering tildipirosin. The product label includes specific warnings regarding the potential for adverse reactions in humans following accidental exposure. Direct contact with the product may cause skin and eye irritation. Handlers should wear appropriate personal protective equipment including impervious gloves and safety glasses or goggles during product handling and administration. In the event of accidental eye exposure, the affected eye should be immediately flushed with copious amounts of clean water for at least 15 minutes, and medical attention should be sought. Skin contact should be addressed by washing the affected area thoroughly with soap and water.

Accidental self-injection is a recognized hazard with any injectable veterinary product and warrants specific precautions. Care should be taken to restrain animals adequately and maintain control of the injection equipment to minimize the risk of accidental human injection. In the event of accidental self-injection, medical attention should be sought immediately. The treating healthcare provider should be informed that the product is a macrolide antibiotic used in veterinary medicine. While the specific effects of tildipirosin following human injection are not fully characterized, local tissue reaction and potential systemic effects warrant medical evaluation. Persons with known hypersensitivity to macrolide antibiotics should take particular care to avoid exposure.

Food safety and residue avoidance are paramount concerns in the use of antimicrobials in food-producing animals. The established withdrawal periods of 21 days for cattle and 7 days for swine must be strictly observed for all treated animals destined for slaughter. No animal should enter the food supply before the withdrawal period has elapsed. Proper identification of treated animals and accurate record-keeping are essential components of residue avoidance programs. Records should include animal identification, treatment date, drug and dose administered, route of administration, and the calculated safe slaughter date. Operations should have systems in place to prevent accidental slaughter of animals still under withdrawal.

Antimicrobial stewardship principles apply to tildipirosin use as they do to all antimicrobials in food animal production. The drug should be used only when bacterial respiratory disease is diagnosed or reasonably suspected based on clinical signs, history, and risk factors. Indiscriminate or purely prophylactic use of antimicrobials promotes the selection of resistant bacterial populations, potentially compromising future treatment options. Tildipirosin should be used as part of a comprehensive health management program that includes appropriate biosecurity, vaccination protocols, nutrition management, and environmental controls. The goal is to minimize the need for antimicrobial treatment through prevention while using antimicrobials judiciously when therapeutic intervention is required.

Environmental considerations govern the proper disposal of unused product and associated materials. Tildipirosin, like all pharmaceuticals, should be disposed of in accordance with applicable federal, state, and local regulations. The drug should not be discharged into waterways, storm drains, or sewage systems. Empty containers should be disposed of according to label directions. Needles, syringes, and other sharps should be placed in approved sharps containers and managed as regulated medical waste. Proper disposal practices help minimize the environmental impact of pharmaceutical residues and reduce the risk of accidental exposure to non-target organisms.

Tildipirosin should be stored under controlled conditions to maintain product potency and stability throughout its shelf life. The recommended storage temperature is between 20°C and 25°C (68°F to 77°F), with permitted excursions to temperatures between 15°C and 30°C (59°F to 86°F). The product should be protected from freezing, as exposure to freezing temperatures may alter the formulation's physical characteristics and potentially affect drug delivery and efficacy. Direct exposure to light should also be avoided, and product should be stored in its original container until use. In farm and feedlot settings where ambient temperatures may fluctuate significantly, storage in climate-controlled areas helps ensure product quality.

Multi-dose vial handling requires attention to aseptic technique to maintain sterility and prevent contamination that could affect both product quality and animal health. Before withdrawing each dose, the rubber stopper should be disinfected with alcohol and allowed to dry. Sterile needles should be used for each entry into the vial, and needles should be changed between animals to prevent disease transmission and vial contamination. Once broached, multi-dose vials should be used within a reasonable timeframe, typically within 28 days unless otherwise specified on the product label. Before each use, the vial contents should be visually inspected for any signs of particulate matter, cloudiness, discoloration, or other changes that might indicate product deterioration or contamination. Any vial showing such changes should be discarded.

Disposal of tildipirosin containers, unused product, and associated administration equipment must comply with all applicable regulations. Empty containers should be triple-rinsed before disposal or recycling according to label instructions and local requirements. Unused or expired product should not be disposed of through regular trash collection or wastewater systems due to potential environmental impacts. Many jurisdictions have pharmaceutical take-back programs or approved disposal facilities for veterinary medications. Sharps including needles and syringes must be placed in approved puncture-resistant containers and disposed of as regulated medical waste according to local requirements. Proper disposal protects the environment, prevents accidental human or animal exposure, and demonstrates responsible stewardship of pharmaceutical products.

Tildipirosin dosing is consistent across all cattle and swine breeds at 4 mg/kg body weight, without breed-specific adjustments. Clinical trials supporting product approval included animals representing the breed diversity typical of commercial cattle and swine production in the United States, establishing efficacy and safety across this range. Whether treating British or Continental beef breeds, dairy breeds, or the various commercial swine genetics, the same weight-based dosing recommendation applies. Accurate body weight determination or estimation remains the critical factor in ensuring appropriate dosing regardless of breed.

Breed-related differences in body composition, metabolism, and susceptibility to respiratory disease may influence how tildipirosin is used in practice, even though they do not change the dosing recommendation. Some cattle breeds are known to be more susceptible to respiratory disease, whether due to anatomical factors, immune function differences, or stress responses. Similarly, certain swine genetic lines may have different susceptibility patterns to respiratory pathogens. These breed-related susceptibility differences affect the overall approach to disease prevention and treatment rather than drug dosing per se. High-risk breeds or genetic lines may benefit from more aggressive metaphylactic programs.

Production system considerations often correlate with breed or genetic type in ways that influence tildipirosin use. Feedlot cattle, frequently crosses of various beef breeds, face intense respiratory disease pressure during the receiving period. Dairy breeds entering beef production through the dairy-beef calf system may have different health challenges and management histories than traditional beef breeds. In swine production, different genetic lines selected for various production traits may be found in different types of operations, from farrow-to-finish to specialized finishing units, each with distinct respiratory disease challenges and management approaches.

Age and weight considerations apply within any breed or genetic type. Very young animals may have different pharmacokinetics and disease dynamics compared to older stock. In cattle, neonatal calves, weaned calves, and yearling cattle represent distinct populations with different treatment considerations. In swine, nursing pigs, weaned pigs, and finishing pigs similarly represent different stages with varying disease challenges and treatment needs. While tildipirosin is approved for use across these age ranges, veterinary guidance is particularly valuable for treatment decisions in very young animals or unusual clinical presentations where limited data may be available.

Within the macrolide antibiotic class, several alternatives to tildipirosin are available for respiratory disease in food animals. Tulathromycin (Draxxin) is another macrolide approved for both cattle and swine, offering single-dose treatment with extended tissue persistence similar to tildipirosin. Gamithromycin (Zactran) is approved for cattle with a comparable single-dose protocol for bovine respiratory disease. Tilmicosin (Micotil) is an older macrolide effective in cattle but notably contraindicated in swine and horses due to fatal cardiovascular toxicity, representing an important distinction from tildipirosin which is safe for swine use. Tylosin (Tylan) has a long history of use in both cattle and swine, available in injectable and feed-grade formulations, though typically used for different indications than acute respiratory disease.

Alternative drug classes provide options when macrolide therapy is not appropriate or when resistance patterns suggest other choices. Fluoroquinolones, including enrofloxacin (Baytril) and danofloxacin (Advocin), offer broad-spectrum bactericidal activity effective against respiratory pathogens. Florfenicol (Nuflor and various generics) provides activity against BRD pathogens including some macrolide-resistant strains. Ceftiofur (Excede, Excenel) represents cephalosporin options with broad-spectrum activity. Tetracyclines including oxytetracycline and chlortetracycline remain widely used, particularly in feed-based applications for swine. The selection among these options depends on pathogen susceptibility, withdrawal time requirements, cost, and practical considerations specific to each operation.

Combination therapy and comprehensive treatment protocols may incorporate tildipirosin alongside other interventions. Anti-inflammatory drugs such as flunixin meglumine or meloxicam are commonly used concurrently with antimicrobials to address the inflammatory component of respiratory disease. In swine, tildipirosin may be part of treatment programs that also include water-soluble medications or feed-grade antimicrobials for population-level disease control. The overall approach to respiratory disease should incorporate prevention through vaccination, biosecurity, and environmental management alongside judicious antimicrobial use when therapeutic intervention is needed. Veterinary consultation helps optimize the selection and combination of therapeutic agents based on the specific situation.